COVID-19 Resources and Studies

COVID-19

Guidance for Resuming Health-Related Human Subjects Research

Guidance on resuming health-related human subjects research and clinical trials has been provided by the Office of the Associate VP for Research, CTSI, and OCR.

Join a COVID-19 Research Study

TitleSummaryRead Details on ClinicalTrials.govStudy ContactsSponsor
Vaccine Trials - CoVPN Volunteer Screening RegistryThe purpose of this screening registry is to create a list of potential volunteers who want to take part in current or future COVID-19 prevention clinical trials. You must be 18 years or older to participate. Participation involves completing a short online survey that includes some personal questions. Your participation is voluntary. This survey typically takes about 10 minutes to complete. Varieswww.coronaviruspreventionnetwork.orgNIAID
Vaccine Trial - ModernaTx The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the efficacy, safety, and immunogenicity of mRNA-1273 to prevent COVID-19 for up to 2 years after the second dose of mRNA-1273.NCT04470427Moderna Clinical Trials
855-663-6762 clinicaltrials@modernatx.com
ModernaTx
Vaccine Trial - PfizerThis study involves comparing an investigational vaccine against a placebo (inactive substance) to see if the investigational vaccine can prevent COVID-19. The vaccine is given by injection.NCT04368728Pfizer CT.gov Call Center
1-800-718-1021 ClinicalTrials.gov_Inquiries@pfizer.com
Pfizer & BioNTECH
A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)Study KIN-1901-2001 is a multi-center, adaptive, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of gimsilumab in subjects with lung injury or acute respiratory distress syndrome (ARDS) secondary to COVID-19.NCT04351243
Lisa Sherman
832-592-3466 lisa.sherman@roivant.com
Kinevant Sciences GmbH
A Multicenter, Randomized-Controlled Trial to Evaluate the Efficacy and Safety of Antithrombotic Therapy for Prevention of Arterial and Venous Thrombotic Complications in Critically-Ill COVID-19 PatientsThis is a multicenter, open-label, 2x2 factorial, randomized-controlled trial in critically-ill patients with novel coronavirus disease 2019 (COVID-19) evaluating the efficacy and safety of full-dose vs. standard prophylactic dose anticoagulation and of antiplatelet vs. no antiplatelet therapy for prevention of venous and arterial thrombotic events.NCT04409834Vivian Baird-Zars
800-385-4444
vbaird-zars@bwh.harvard.edu
The TIMI Study Group
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)The purpose of this study is to evaluate the efficacy and safety of ruxolitinib in the treatment of participants with COVID-19-associated Acute Respiratory Distress Syndrome (ARDS) who require mechanical ventilation.NCT04377620
UF Pending Incyte Corporation
Clinical-trial of COVID-19 Convalescent Plasma in Outpatients
The primary objective is to determine the efficacy and safety of a single dose of convalescent plasma (CP) for preventing the progression from mild to severe COVID-19 illness. NCT04355767UF Pending Stanford University
Healthcare Worker Exposure Response and Outcomes (HERO) Registry Study, COVID-19The HERO Registry provides a resource for collecting information on Healthcare Workers (HCWs) currently working in the United States. NCT04342806Laura Webb
(919) 668-8977
heroesresearch@duke.edu

Nina Y Hines
(919) 668-3677
heroesresearch@duke.edu
Duke University
Mental Health Impact of COVID-19 Pandemic StudyThe purpose of this study is to learn about how stressors related to the COVID-19 virus affect mental health over time. We hope to better understand the experiences of participants during this difficult time. Participation involves completing online questionnaires every two weeks, for 6 months. The questionnaires take about 20 minutes to complete. You must be at least 18 years old to participate.NCT04339790To find out if you qualify, email NIMHResearchVolunteer@nih.gov or call 1-240-665-0697 [TTY: 1-866-411-1010].National Institute of Mental Health (NIMH)
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History StudyThis study collects blood samples, medical information, and medical images from patients who are being treated for cancer and have a positive test for SARS CoV-2, the new coronavirus that causes the disease called COVID-19. Collecting blood samples, medical information, and medical images may help researchers determine how COVID-19 affects the outcomes of patients undergoing cancer treatment and how having cancer affects COVID-19.NCT04387656
Site Public Contact
352-273-8010
cancer-center@ufl.edu
National Cancer Institute (NCI)
Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease (ORCHID)ORCHID is a multicenter, blinded, placebo-controlled, randomized clinical trial evaluating hydroxychloroquine for the treatment of adults hospitalized with COVID-19. NCT04332991

Katie Oldmixon, RN
(617) 726-4777
coldmixon@mgh.harvard.edu

Nancy Ringwood, BSN
(617) 724-9836
nringwood@mgh.harvard.edu
Massachusetts General Hospital & National Heart, Lung, and Blood Institute (NHLBI)
Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring HospitalizationThis is a multi-center, double-blinded study of COVID-19 infected patients requiring inpatient hospital admission randomized 1:1 to daily Losartan or placebo for 7 days or hospital discharge.NCT04312009
Christopher Tignanelli, MD 612-624-4373 Covid19trial@umn.edu

Michael Puskarich, MD, MS 612-624-4373 Covid19trial@umn.edu
University of Minnesota
SARS-COV2 Pandemic Serosurvey and Blood SamplingIn this study, researchers want to find people who have anti-SARS-COV2 antibodies but no known exposure or illness.NCT04334954    clinicalstudiesunit@nih.govNational Institute of Allergy and Infectious Diseases (NIAID)
Smell Loss and COVID-19Only individuals who have been tested for COVID-19 at a UF Health clinic may participate in this study.N/Ahttps://ufhealth.org/research-study/smell-loss-and-covid-19-study
 
University of Florida
University of Florida COVID-19 Testing Program in The VillagesThe University of Florida is offering drive-thru coronavirus tests for residents at The Villages who are experiencing symptoms and meet certain other requirements.N/AUFHealthCovid.com
University of Florida
Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry and Validation of C2D2 (Critical Care Data Dictionary)Researchers are creating a real time COVID-19 registry of current ICU/hospital care patterns to allow evaluations of safety and observational effectiveness of COVID-19 practices and to determine the variations in practice across hospitals.NCT04323787Mayo Clinic

Office of Clinical Research

UF Clinical Research Resumption Plan

The UF Office of Clinical Research has published guidance for resuming clinical research projects, which applies to all UF health-related human…

Back in the Lab

Updates to PPE Requirements for Research Staff

In an ongoing effort to reduce the risks of potential exposure to COVID-19, UF Health continues to update guidance on PPE (Personal Protection…

Mask and eye protection

UF|Research Resumption Plan – Stage 3

The University of Florida has now begun Stage 3 in the process for reengaging on-campus research activities which have been interrupted by the…

Nurse Taking Patient Temperature Wearing Masks

Resources

Alachua County

Centers for Disease Control and Prevention

FDA

Florida Department of Health

National Institutes of Health

University of Florida

UF Clinical Research Forum

UF COVID-19 Scientific Review Committee

  • UFHealth has established a committee to review and prioritize COVID 19 related research. Final approval from the IRB will be contingent on receiving communication from this committee that your study has been approved to move forward. If your study will involve UFHealth hospital or clinic patients, please e-mail the COVID-19 Scientific Review Committee and Peer Assistance Working Group (SRCWG) via covid_srcwg@ahc.ufl.edu.

UF Emerging Pathogens Institute

UF Health

UF Human Resources

UF IRB

UF Health IT

UF OnCore

UF | Research

World Health Organization (WHO)